Trojan Bio develops in-vivo T-cell therapies based on Antibody Epitope Conjugates (AECs), enabling CAR-T–like efficacy through standard antibody delivery.

These antibodies are engineered to carry concealed viral peptides within their structure. Once internalized into the target cancer cell, the embedded peptides label the tumor as virally infected. This viral labeling triggers potent activation of antiviral T cells, effectively converting the patient’s own T cells into in-vivo CAR-T–like effectors.

Our lead program, the therapeutic antibody TRJ-316, targets CD70 and is being developed for metastatic clear-cell renal cell carcinoma (ccRCC).

TRJ-316 has demonstrated strong in-vivo anti-tumor activity and is well positioned for combination strategies with standard-of-care therapies, complementing both immune-checkpoint inhibition and tumor-microenvironment modulation.